Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Based on a post hoc analysis, fewer required respiratory interventions
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
In the interim, Deepak Khanna will lead Human Health International.
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Subscribe To Our Newsletter & Stay Updated
